Adaptive Biotechnologies (ADPT) Receivables - Other (2018 - 2026)

Adaptive Biotechnologies has disclosed Receivables - Other across 9 years of filings, most recently posting $1.6 million for Q1 2026.

• Receivables - Other for Q1 2026 came in at $1.6 million, up 6.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (up 6.67% YoY), and the FY2025 annual result was $1.5 million, up 15.38% from the prior year.
• Receivables - Other came in at $1.6 million for Q1 2026 at Adaptive Biotechnologies, up from $1.5 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $1.6 million in Q1 2026 to a low of $800000.0 in Q2 2022.
• The 5-year median for Receivables - Other is $1.1 million (2022), against an average of $1.2 million.
• Across the five-year window, Receivables - Other tumbled 65.22% in 2022 and soared 36.36% in 2025, its largest moves.
• Adaptive Biotechnologies' Receivables - Other stood at $800000.0 in 2022, then gained by 25.0% to $1.0 million in 2023, then climbed by 30.0% to $1.3 million in 2024, then grew by 15.38% to $1.5 million in 2025, then rose by 6.67% to $1.6 million in 2026.
• The last three Receivables - Other figures came in at $1.6 million (Q1 2026), $1.5 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.